Nanobody Market Share,Latest Innovations, Drivers, Dynamics And Strategic Analysis, Challenges 2030

Comments · 189 Views

Due to the COVID-19 pandemic, drug development and research efforts have intensified, adding pressure on the healthcare industry.

Nanobody Market Overview

Due to the COVID-19 pandemic, drug development and research efforts have intensified, adding pressure on the healthcare industry. 

The global market of nanobody is driven by various factors, such as rising healthcare expenditure and increasing investments in RD activities to develop nanobody-based therapeutics. In addition, the growing usage of nanobodies in various applications such as in vivo imaging, antivenom therapy, and immune-based therapeutics among others is also driving the market growth of the nanobody. Moreover, the progress of various nanobody products in clinical trials and their subsequent approval further boost the growth of the market. Furthermore, rising health-related concerns coupled with favorable reimbursement policies for availing healthcare services are anticipated to fuel the growth of the nanobody market during the forecast period.

According to MRFR analysis, the global nanobody market share is expected to register a CAGR of 24.2% from 2022 to 2030 and hold a value of over USD 1.14 billion by 2030.

Nanobody Market Regional Analysis

North America is likely to dominate the nanobody market, owing to increasing investments in RD by the key players research institutes coupled with well developed healthcare infrastructure in the region. Furthermore, the presence of major industry players across the region, such as Thermo Fisher Scientific Inc. (US), Sensei Biotherapeutics, Inc. (US), Cusabio Technology LLC (US), and other players are further contributing to the regional growth.

Europe is likely to account for a significant share of the nanobody market Trends due to the presence of a well-developed healthcare infrastructure and high healthcare expenditure. For instance, according to the Eurostat database, healthcare expenditure was 8.0% of GDP in 2020. Moreover, the rising product approvals from regulatory bodies is also expected to drive the growth of the market in Europe during the forecast period. For instance, in September 2018, Cablivi (Caplacizumab) was granted marketing authorization by the European Commission for the treatment of Acquired Thrombotic Thrombocytopenic Purpura (aTTP) in adults.

Asia-Pacific is projected to be the fastest-growing regional market during the forecast period due to factors like improved healthcare infrastructure and a high percentage of the geriatric population in the region demanding efficient therapeutics. Furthermore, initiatives undertaken by key players to expand operations in the region are also boosting the market growth.

Furthermore, the growth of the market in the Rest of the World is slower compared to the other regions due to the limited healthcare infrastructure and fewer research activities. However, increasing government initiatives for improving the healthcare sector and the rising prevalence of cancer and other chronic diseases are expected to drive the market over the forecast period.

KeyPlayer

Nanobody Market players are Sanofi S.A. (France), Merck KGaA (Germany), Alphamab Oncology (China), Bristol Myers Squibb (US), Novartis AG (Switzerland), GenScript Biotech Corporation (US), Sensei Biotherapeutics (US), Beroni Group (Australia), DiosCURE Therapeutics SE (Germany), ExeVir Bio BV (Belgium), and Taisho Pharmaceutical Holdings Co., Ltd. (Japan).

Nanobody Market Segmentation

The global nanobody market Outlook has been segmented into type, application, and end user.

Based on type, the market has been segmented into mono-specific and multi-specific. The mono-specific segment held a larger market share in 2021. The mono-specific nanobody available in the market incuded Cablivi (Caplacizumab) marketed by Sanofi S.A. (France). In addition, many pharmaceutical organizations are investing in RD for the discovery and development of novel multi-specific nanobody drug candidates. Thus, many multi-specific nanobody drug candidates are in various phases of clinical trials for the treatment of cancer and other chronic diseases.

Based on application, the market has been segmented into therapeutic, diagnostic, and research.

The therapeutic segment is further segmented into cancer, neurodegenerative diseases, infectious diseases, and others.  The diagnostic segment is further segmented into the detection of proteins and microorganisms, detection of small molecules, and imaging.

Based on end user, the market has been segmented into pharmaceutical biotechnology companies, research laboratories, and others. The pharmaceutical biotechnology companies segment held the highest share in 2021, due to the rising investment in RD activities for the development of nanobody-based new therapeutics for the treatment of chronic disorders such as neurodegenerative diseases, rheumatoid arthritis, osteoporosis, and other conditions.

 

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street, 5Th Floor,

New York, New York 10013

United States of America

+1 628 258 0071

Email: sales@marketresearchfuture.com

 

 

 

 

Comments